Short excerpt
The U.S. Food and Drug Administration’s risk-benefit assessment in connection with Pfizer’s application for emergency use of its COVID vaccine for children 5 to 11 describes only relative risks in an older population. It ignores absolute risk and also the standard calculation for measuring a drug’s effectiveness — Number Needed To Vaccinated (NNTV).
Comments
Loading…